Pfizer announced trial results for its investigational Covid-19 oral antiviral candidate, Paxlovid, saying it significantly reduced hospitalisation and death.-why-is-google-doodle-celebrating-her-biceived ‘heaviest rainfall’ since 2015.
About
It is an investigational SARS-CoV-2 “protease inhibitor antiviral therapy”.
It inhibits viral replication at proteolysis, a stage that occurs before viral replication.
It is “designed to be administered orally so that it can be prescribed at the first sign of infection or at first awareness of an exposure, potentially helping patients avoid severe illness.”
Pfizer said it has entered into advance purchase agreements with “multiple countries and is in negotiations with several others”.
